Association between TriptanUse and Cardiac Contraindications in an Insured Migraine Population

Authors

Daisy Ng-Mak, PhD, Global Health Outcomes, Merck Sharp & DohmeCorp., West Point, PA, USAFollow
Valerie P. Pracilio, MPH, Jefferson School of Population HealthFollow
Stephen Silberstein, MD, Jefferson Headache CenterFollow
Joseph Couto, PharmD, MBA, Jefferson School of Population HealthFollow
Cary Sennett, MD, PhD, MedAssurant, Inc.Follow
Mary Hopkins, RN, Jefferson Headache CenterFollow
Jon Bumbaugh, MedAssurant, Inc.
Neil I. Goldfarb, Jefferson School of Population HealthFollow

Document Type

Presentation

Publication Date

2-2012

Abstract

Background

Safety concerns exist when using triptansto treat patients with cardiac contraindications.

–Triptans cause vasoconstriction, a safety concern for migraineurswith cardiovascular (CV) disease or other cardiac risk factors.

–All triptans contain contraindications in their package inserts to avoid use in patients with cardiac conditions.

•Previous research indicates that clinicians are less likely to prescribe triptansin patients with CV disease or CV risk factors.

Limited research has examined the proportion of migraine patients with cardiovascular disease or those individuals who were concurrently treated with triptans.

Recommended Citation

Ng-Mak, PhD, Daisy; Pracilio, MPH, Valerie P.; Silberstein, MD, Stephen; Couto, PharmD, MBA, Joseph; Sennett, MD, PhD, Cary; Hopkins, RN, Mary; Bumbaugh, Jon; and Goldfarb, Neil I., "Association between TriptanUse and Cardiac Contraindications in an Insured Migraine Population" (2012). College of Population Health Lectures, Presentations, Workshops. Paper 23.
https://jdc.jefferson.edu/hplectures/23